Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

Jeffrey C. Thompson,Erica L. Carpenter,Benjamin A. Silva,Jamie Rosenstein,Austin L. Chien,Katie Quinn,Carin R. Espenschied,Allysia Mak,Lesli A. Kiedrowski,Martina Lefterova,Rebecca J. Nagy,Sharyn I. Katz,Stephanie S. Yee,Taylor A. Black,Aditi P. Singh,Christine Ciunci,Joshua Bauml,Roger B. Cohen,Corey J. Langer,Charu Aggarwal

Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

2021

PURPOSEAlthough the majority of patients with metastatic non–small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setti...

Keywords:

Mutation
Circulating tumor DNA
Lung cancer
DNA sequencing
Cancer research
Pembrolizumab
Medicine
Biomarker (medicine)
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations